AU2007212786B2 - Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'H)-triones for treatment of conditions associated with vanilloid receptor 1 - Google Patents

Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'H)-triones for treatment of conditions associated with vanilloid receptor 1 Download PDF

Info

Publication number
AU2007212786B2
AU2007212786B2 AU2007212786A AU2007212786A AU2007212786B2 AU 2007212786 B2 AU2007212786 B2 AU 2007212786B2 AU 2007212786 A AU2007212786 A AU 2007212786A AU 2007212786 A AU2007212786 A AU 2007212786A AU 2007212786 B2 AU2007212786 B2 AU 2007212786B2
Authority
AU
Australia
Prior art keywords
pain
chronic
compound
acute
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007212786A
Other languages
English (en)
Other versions
AU2007212786A1 (en
AU2007212786A8 (en
Inventor
Carmen Leung
Miroslaw Tomaszewski
Simon Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007212786(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2007212786A1 publication Critical patent/AU2007212786A1/en
Publication of AU2007212786A8 publication Critical patent/AU2007212786A8/en
Application granted granted Critical
Publication of AU2007212786B2 publication Critical patent/AU2007212786B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
AU2007212786A 2006-02-07 2007-02-06 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'H)-triones for treatment of conditions associated with vanilloid receptor 1 Ceased AU2007212786B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07
US60/771,119 2006-02-07
PCT/SE2007/000107 WO2007091947A2 (en) 2006-02-07 2007-02-06 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1

Publications (3)

Publication Number Publication Date
AU2007212786A1 AU2007212786A1 (en) 2007-08-16
AU2007212786A8 AU2007212786A8 (en) 2010-05-06
AU2007212786B2 true AU2007212786B2 (en) 2011-06-02

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007212786A Ceased AU2007212786B2 (en) 2006-02-07 2007-02-06 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'H)-triones for treatment of conditions associated with vanilloid receptor 1

Country Status (21)

Country Link
US (2) US20070185179A1 (enExample)
EP (1) EP2013215A4 (enExample)
JP (1) JP2009526043A (enExample)
KR (1) KR20080094906A (enExample)
CN (1) CN101415711A (enExample)
AR (1) AR059265A1 (enExample)
AU (1) AU2007212786B2 (enExample)
BR (1) BRPI0707423A2 (enExample)
CA (1) CA2641632A1 (enExample)
CL (1) CL2009000523A1 (enExample)
IL (1) IL192890A0 (enExample)
NO (1) NO20083547L (enExample)
NZ (1) NZ571070A (enExample)
RU (1) RU2421457C2 (enExample)
SA (1) SA07280027B1 (enExample)
SG (1) SG169387A1 (enExample)
TW (1) TW200801011A (enExample)
UA (1) UA93226C2 (enExample)
UY (1) UY30132A1 (enExample)
WO (1) WO2007091947A2 (enExample)
ZA (1) ZA200806407B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921576B2 (en) 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066378A1 (en) * 1981-05-12 1982-12-08 Imperial Chemical Industries Plc Pharmaceutical spiro-hydantoin derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
JP2003505388A (ja) * 1999-07-21 2003-02-12 アストラゼネカ・アクチエボラーグ 新規化合物
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AU2004247559B2 (en) 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
WO2007091948A2 (en) 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066378A1 (en) * 1981-05-12 1982-12-08 Imperial Chemical Industries Plc Pharmaceutical spiro-hydantoin derivatives

Also Published As

Publication number Publication date
AR059265A1 (es) 2008-03-19
WO2007091947A3 (en) 2007-10-04
US7868181B2 (en) 2011-01-11
IL192890A0 (en) 2009-02-11
EP2013215A4 (en) 2010-09-08
UA93226C2 (en) 2011-01-25
EP2013215A2 (en) 2009-01-14
KR20080094906A (ko) 2008-10-27
AU2007212786A1 (en) 2007-08-16
ZA200806407B (en) 2009-04-29
JP2009526043A (ja) 2009-07-16
BRPI0707423A2 (pt) 2011-05-03
TW200801011A (en) 2008-01-01
NZ571070A (en) 2011-07-29
US20090137650A1 (en) 2009-05-28
WO2007091947A2 (en) 2007-08-16
UY30132A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
SG169387A1 (en) 2011-03-30
RU2421457C2 (ru) 2011-06-20
CN101415711A (zh) 2009-04-22
SA07280027B1 (ar) 2010-11-22
RU2008131905A (ru) 2010-03-20
NO20083547L (no) 2008-11-05
CL2009000523A1 (es) 2009-07-17
US20070185179A1 (en) 2007-08-09
AU2007212786A8 (en) 2010-05-06
WO2007091947A8 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
EP1786773B1 (en) Isoindolin-1-one derivatives
ES2325861T3 (es) Moduladores triciclicos de receptores nucleares de hormosas esteroideas.
TW202024019A (zh) 聯苯類化合物，其中間體，製備方法，藥物組合物及應用
JP2008013556A (ja) 新規ナフタレン化合物、その製造法、およびそれを含有する薬学的組成物
WO2017170830A1 (ja) 複素環化合物
JP2009526044A (ja) 新規な化合物ｉ
WO2018181345A1 (ja) 複素環化合物
JP2009544623A (ja) モルホリニルおよびピロリジニル類似体
BRPI0715872A2 (pt) Composto; composição farmacêutica; método de preparação do composto; composto preparado pelo método; e método de tratamento de um transtorno em um mamífero necessitado
ES2259096T3 (es) Derivados de quinolina-4-carboxamida 3-sustituida como antagonistas de los receptores nk-3 y nk-2.
JP4986927B2 (ja) 医薬
TWI360540B (en) Tetrahydroisoquinolylsulphonamide derivatives, the
AU2011310078A1 (en) Chromene derivatives
US7868181B2 (en) Compounds
JP2015521994A (ja) イミダゾ［２，１−ｂ］チアゾール誘導体、その製造方法、および医薬品としての使用
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
CN116082259B (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
EP3022177B1 (en) Indole-3-carbinol derivatives
MX2008009999A (es) Novedosos espiro[imidazolidina-4,3'-indol]-2,2',5(1'4)-triones para tratamiento de condiciones asociadas con receptor 1 vaniloide
EP1833809A1 (en) New benzothiazolecarboxamides
TWI891070B (zh) 一種含螺環類衍生物的鹽、晶型及其製備方法和應用
CN114890963B (zh) 苯亚甲基噻唑烷二酮类衍生物及其制备方法和应用
RU2155748C2 (ru) Производные циклогексадиена, смесь их изомеров или отдельные изомеры и их соли и фармацевтическая композиция с избирательным модулирующим действием на зависимые от кальция калиевые канальцы высокой проводимости
JPH04225954A (ja) アミド化合物、その医薬用途および新規１−置換ピロリジンメチルアミン類
CN101415712A (zh) 螺[咪唑烷-4,3’-吲哚]2,2’,5’(1h)三酮在治疗与香草素受体1有关的疾病中的用途

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 22, NO 33, PAGE(S) 3904 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ASTRAZENECA AB, APPLICATION NO. 2007212786, UNDER INID (54) CORRECT THE TITLE TO READ NOVEL SPIRO[IMIDAZOLIDINE-4,3 -INDOLE]-2,2 ,5(1 H)-TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired